Recombinant monovalent llama-derived antibody fragments (VHH) to rotavirus VP6 protect neonatal gnotobiotic piglets against human rotavirus-induced diarrhea.

Group A Rotavirus (RVA) is the leading cause of severe diarrhea in children. The aims of the present study were to determine the neutralizing activity of VP6-specific llama-derived single domain nanoantibodies (VHH nanoAbs) against different RVA strains in vitro and to evaluate the ability of G6P[1]...

Full description

Bibliographic Details
Main Authors: Celina G Vega, Marina Bok, Anastasia N Vlasova, Kuldeep S Chattha, Silvia Gómez-Sebastián, Carmen Nuñez, Carmen Alvarado, Rodrigo Lasa, José M Escribano, Lorena L Garaicoechea, Fernando Fernandez, Karin Bok, Andrés Wigdorovitz, Linda J Saif, Viviana Parreño
Format: Article
Language:English
Published: Public Library of Science (PLoS) 2013-01-01
Series:PLoS Pathogens
Online Access:http://europepmc.org/articles/PMC3642062?pdf=render
_version_ 1818981442867167232
author Celina G Vega
Marina Bok
Anastasia N Vlasova
Kuldeep S Chattha
Silvia Gómez-Sebastián
Carmen Nuñez
Carmen Alvarado
Rodrigo Lasa
José M Escribano
Lorena L Garaicoechea
Fernando Fernandez
Karin Bok
Andrés Wigdorovitz
Linda J Saif
Viviana Parreño
author_facet Celina G Vega
Marina Bok
Anastasia N Vlasova
Kuldeep S Chattha
Silvia Gómez-Sebastián
Carmen Nuñez
Carmen Alvarado
Rodrigo Lasa
José M Escribano
Lorena L Garaicoechea
Fernando Fernandez
Karin Bok
Andrés Wigdorovitz
Linda J Saif
Viviana Parreño
author_sort Celina G Vega
collection DOAJ
description Group A Rotavirus (RVA) is the leading cause of severe diarrhea in children. The aims of the present study were to determine the neutralizing activity of VP6-specific llama-derived single domain nanoantibodies (VHH nanoAbs) against different RVA strains in vitro and to evaluate the ability of G6P[1] VP6-specific llama-derived single domain nanoantibodies (VHH) to protect against human rotavirus in gnotobiotic (Gn) piglets experimentally inoculated with virulent Wa G1P[8] rotavirus. Supplementation of the daily milk diet with 3B2 VHH clone produced using a baculovirus vector expression system (final ELISA antibody -Ab- titer of 4096; virus neutralization -VN- titer of 256) for 9 days conferred full protection against rotavirus associated diarrhea and significantly reduced virus shedding. The administration of comparable levels of porcine IgG Abs only protected 4 out of 6 of the animals from human RVA diarrhea but significantly reduced virus shedding. In contrast, G6P[1]-VP6 rotavirus-specific IgY Abs purified from eggs of hyperimmunized hens failed to protect piglets against human RVA-induced diarrhea or virus shedding when administering similar quantities of Abs. The oral administration of VHH nanoAb neither interfered with the host's isotype profiles of the Ab secreting cell responses to rotavirus, nor induced detectable host Ab responses to the treatment in serum or intestinal contents. This study shows that the oral administration of rotavirus VP6-VHH nanoAb is a broadly reactive and effective treatment against rotavirus-induced diarrhea in neonatal pigs. Our findings highlight the potential value of a broad neutralizing VP6-specific VHH nanoAb as a treatment that can complement or be used as an alternative to the current strain-specific RVA vaccines. Nanobodies could also be scaled-up to develop pediatric medication or functional food like infant milk formulas that might help treat RVA diarrhea.
first_indexed 2024-12-20T17:31:24Z
format Article
id doaj.art-4d85d24c4607410ba310e98165981f63
institution Directory Open Access Journal
issn 1553-7366
1553-7374
language English
last_indexed 2024-12-20T17:31:24Z
publishDate 2013-01-01
publisher Public Library of Science (PLoS)
record_format Article
series PLoS Pathogens
spelling doaj.art-4d85d24c4607410ba310e98165981f632022-12-21T19:31:22ZengPublic Library of Science (PLoS)PLoS Pathogens1553-73661553-73742013-01-0195e100333410.1371/journal.ppat.1003334Recombinant monovalent llama-derived antibody fragments (VHH) to rotavirus VP6 protect neonatal gnotobiotic piglets against human rotavirus-induced diarrhea.Celina G VegaMarina BokAnastasia N VlasovaKuldeep S ChatthaSilvia Gómez-SebastiánCarmen NuñezCarmen AlvaradoRodrigo LasaJosé M EscribanoLorena L GaraicoecheaFernando FernandezKarin BokAndrés WigdorovitzLinda J SaifViviana ParreñoGroup A Rotavirus (RVA) is the leading cause of severe diarrhea in children. The aims of the present study were to determine the neutralizing activity of VP6-specific llama-derived single domain nanoantibodies (VHH nanoAbs) against different RVA strains in vitro and to evaluate the ability of G6P[1] VP6-specific llama-derived single domain nanoantibodies (VHH) to protect against human rotavirus in gnotobiotic (Gn) piglets experimentally inoculated with virulent Wa G1P[8] rotavirus. Supplementation of the daily milk diet with 3B2 VHH clone produced using a baculovirus vector expression system (final ELISA antibody -Ab- titer of 4096; virus neutralization -VN- titer of 256) for 9 days conferred full protection against rotavirus associated diarrhea and significantly reduced virus shedding. The administration of comparable levels of porcine IgG Abs only protected 4 out of 6 of the animals from human RVA diarrhea but significantly reduced virus shedding. In contrast, G6P[1]-VP6 rotavirus-specific IgY Abs purified from eggs of hyperimmunized hens failed to protect piglets against human RVA-induced diarrhea or virus shedding when administering similar quantities of Abs. The oral administration of VHH nanoAb neither interfered with the host's isotype profiles of the Ab secreting cell responses to rotavirus, nor induced detectable host Ab responses to the treatment in serum or intestinal contents. This study shows that the oral administration of rotavirus VP6-VHH nanoAb is a broadly reactive and effective treatment against rotavirus-induced diarrhea in neonatal pigs. Our findings highlight the potential value of a broad neutralizing VP6-specific VHH nanoAb as a treatment that can complement or be used as an alternative to the current strain-specific RVA vaccines. Nanobodies could also be scaled-up to develop pediatric medication or functional food like infant milk formulas that might help treat RVA diarrhea.http://europepmc.org/articles/PMC3642062?pdf=render
spellingShingle Celina G Vega
Marina Bok
Anastasia N Vlasova
Kuldeep S Chattha
Silvia Gómez-Sebastián
Carmen Nuñez
Carmen Alvarado
Rodrigo Lasa
José M Escribano
Lorena L Garaicoechea
Fernando Fernandez
Karin Bok
Andrés Wigdorovitz
Linda J Saif
Viviana Parreño
Recombinant monovalent llama-derived antibody fragments (VHH) to rotavirus VP6 protect neonatal gnotobiotic piglets against human rotavirus-induced diarrhea.
PLoS Pathogens
title Recombinant monovalent llama-derived antibody fragments (VHH) to rotavirus VP6 protect neonatal gnotobiotic piglets against human rotavirus-induced diarrhea.
title_full Recombinant monovalent llama-derived antibody fragments (VHH) to rotavirus VP6 protect neonatal gnotobiotic piglets against human rotavirus-induced diarrhea.
title_fullStr Recombinant monovalent llama-derived antibody fragments (VHH) to rotavirus VP6 protect neonatal gnotobiotic piglets against human rotavirus-induced diarrhea.
title_full_unstemmed Recombinant monovalent llama-derived antibody fragments (VHH) to rotavirus VP6 protect neonatal gnotobiotic piglets against human rotavirus-induced diarrhea.
title_short Recombinant monovalent llama-derived antibody fragments (VHH) to rotavirus VP6 protect neonatal gnotobiotic piglets against human rotavirus-induced diarrhea.
title_sort recombinant monovalent llama derived antibody fragments vhh to rotavirus vp6 protect neonatal gnotobiotic piglets against human rotavirus induced diarrhea
url http://europepmc.org/articles/PMC3642062?pdf=render
work_keys_str_mv AT celinagvega recombinantmonovalentllamaderivedantibodyfragmentsvhhtorotavirusvp6protectneonatalgnotobioticpigletsagainsthumanrotavirusinduceddiarrhea
AT marinabok recombinantmonovalentllamaderivedantibodyfragmentsvhhtorotavirusvp6protectneonatalgnotobioticpigletsagainsthumanrotavirusinduceddiarrhea
AT anastasianvlasova recombinantmonovalentllamaderivedantibodyfragmentsvhhtorotavirusvp6protectneonatalgnotobioticpigletsagainsthumanrotavirusinduceddiarrhea
AT kuldeepschattha recombinantmonovalentllamaderivedantibodyfragmentsvhhtorotavirusvp6protectneonatalgnotobioticpigletsagainsthumanrotavirusinduceddiarrhea
AT silviagomezsebastian recombinantmonovalentllamaderivedantibodyfragmentsvhhtorotavirusvp6protectneonatalgnotobioticpigletsagainsthumanrotavirusinduceddiarrhea
AT carmennunez recombinantmonovalentllamaderivedantibodyfragmentsvhhtorotavirusvp6protectneonatalgnotobioticpigletsagainsthumanrotavirusinduceddiarrhea
AT carmenalvarado recombinantmonovalentllamaderivedantibodyfragmentsvhhtorotavirusvp6protectneonatalgnotobioticpigletsagainsthumanrotavirusinduceddiarrhea
AT rodrigolasa recombinantmonovalentllamaderivedantibodyfragmentsvhhtorotavirusvp6protectneonatalgnotobioticpigletsagainsthumanrotavirusinduceddiarrhea
AT josemescribano recombinantmonovalentllamaderivedantibodyfragmentsvhhtorotavirusvp6protectneonatalgnotobioticpigletsagainsthumanrotavirusinduceddiarrhea
AT lorenalgaraicoechea recombinantmonovalentllamaderivedantibodyfragmentsvhhtorotavirusvp6protectneonatalgnotobioticpigletsagainsthumanrotavirusinduceddiarrhea
AT fernandofernandez recombinantmonovalentllamaderivedantibodyfragmentsvhhtorotavirusvp6protectneonatalgnotobioticpigletsagainsthumanrotavirusinduceddiarrhea
AT karinbok recombinantmonovalentllamaderivedantibodyfragmentsvhhtorotavirusvp6protectneonatalgnotobioticpigletsagainsthumanrotavirusinduceddiarrhea
AT andreswigdorovitz recombinantmonovalentllamaderivedantibodyfragmentsvhhtorotavirusvp6protectneonatalgnotobioticpigletsagainsthumanrotavirusinduceddiarrhea
AT lindajsaif recombinantmonovalentllamaderivedantibodyfragmentsvhhtorotavirusvp6protectneonatalgnotobioticpigletsagainsthumanrotavirusinduceddiarrhea
AT vivianaparreno recombinantmonovalentllamaderivedantibodyfragmentsvhhtorotavirusvp6protectneonatalgnotobioticpigletsagainsthumanrotavirusinduceddiarrhea